Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jacques Medioni

Showing results (41-50 of 60) with videos related to

Pageof 6
Sort By:
Cancer Research|July 3, 2004
Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterationsPascal Leuraud, Luc Taillandier, Jacques Medioni, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 16, 2010
A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patientsOlivier Adotevi, Helene Pere, Patrice Ravel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2016
A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic MiceThi Tran, Mariana O Diniz, Estelle Dransart, et al.
Pediatrics|May 3, 2003
Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patientsSophie Dupuis-Girod, Jacques Medioni, Elie Haddad, et al.
Lung Cancer (Amsterdam, Netherlands)|August 21, 2003
Three irradiation treatment options including radiosurgery for brain metastases from primary lung cancerGeorges Noel, Jacques Medioni, Charles-Ambroise Valery, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter StudyMaud Velev, Alicja Puszkiel, Benoit Blanchet, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 12, 2025
Improved tumor-type informed compared to tumor-informed mutation tracking for ctDNA detection and microscopic residual disease assessment in epithelial ovarian cancerMehdi Ben Sassi, Henri Azais, Charles Marcaillou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2014
Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patientsJacques Medioni, Gael Deplanque, Jean-Marc Ferrero, et al.
International Journal of Radiation Oncology, Biology, Physics|December 14, 2025
Multicenter Retrospective Analysis of the Safety and Efficacy of Sacituzumab Govitecan Combined With Radiation Therapy: The French ATTENTION StudyAurelia Alati, Kamel Debbi, Nathaniel Scher, et al.
Annales De Pathologie|February 13, 2020
[Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications]Meriem Koual, Géraldine Perkins, Nicolas Delanoy, et al.
Pageof 6

Showing results (41-50 of 60) with videos related to

Sort By:
Pageof 6
Cancer Research|July 3, 2004
Distinct responses of xenografted gliomas to different alkylating agents are related to histology and genetic alterationsPascal Leuraud, Luc Taillandier, Jacques Medioni, et al.
Journal of Immunotherapy (Hagerstown, Md. : 1997)|October 16, 2010
A decrease of regulatory T cells correlates with overall survival after sunitinib-based antiangiogenic therapy in metastatic renal cancer patientsOlivier Adotevi, Helene Pere, Patrice Ravel, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|March 24, 2016
A Therapeutic Her2/neu Vaccine Targeting Dendritic Cells Preferentially Inhibits the Growth of Low Her2/neu-Expressing Tumor in HLA-A2 Transgenic MiceThi Tran, Mariana O Diniz, Estelle Dransart, et al.
Pediatrics|May 3, 2003
Autoimmunity in Wiskott-Aldrich syndrome: risk factors, clinical features, and outcome in a single-center cohort of 55 patientsSophie Dupuis-Girod, Jacques Medioni, Elie Haddad, et al.
Lung Cancer (Amsterdam, Netherlands)|August 21, 2003
Three irradiation treatment options including radiosurgery for brain metastases from primary lung cancerGeorges Noel, Jacques Medioni, Charles-Ambroise Valery, et al.
Pharmaceuticals (Basel, Switzerland)|August 28, 2021
Association between Olaparib Exposure and Early Toxicity in BRCA-Mutated Ovarian Cancer Patients: Results from a Retrospective Multicenter StudyMaud Velev, Alicja Puszkiel, Benoit Blanchet, et al.
Journal of Experimental & Clinical Cancer Research : CR|June 12, 2025
Improved tumor-type informed compared to tumor-informed mutation tracking for ctDNA detection and microscopic residual disease assessment in epithelial ovarian cancerMehdi Ben Sassi, Henri Azais, Charles Marcaillou, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 12, 2014
Phase I safety and pharmacodynamic of inecalcitol, a novel VDR agonist with docetaxel in metastatic castration-resistant prostate cancer patientsJacques Medioni, Gael Deplanque, Jean-Marc Ferrero, et al.
International Journal of Radiation Oncology, Biology, Physics|December 14, 2025
Multicenter Retrospective Analysis of the Safety and Efficacy of Sacituzumab Govitecan Combined With Radiation Therapy: The French ATTENTION StudyAurelia Alati, Kamel Debbi, Nathaniel Scher, et al.
Annales De Pathologie|February 13, 2020
[Hereditary breast and ovarian cancer syndrome: Diagnosis and therapeutic implications]Meriem Koual, Géraldine Perkins, Nicolas Delanoy, et al.
Pageof 6